UNICREDIT BANK/CALL/GSK PLC/1700/1/18.09.24 Stock

Warrant

DE000HD03455

Market Closed - BOERSE MUENCHEN 15:45:57 2024-06-28 EDT
0.23 EUR +9.52% Intraday chart for UNICREDIT BANK/CALL/GSK PLC/1700/1/18.09.24
Current month-85.44%
1 month-84.03%
Date Price Change
24-06-28 0.23 +9.52%
24-06-27 0.21 -46.15%
24-06-26 0.39 +5.41%
24-06-25 0.37 -17.78%
24-06-24 0.45 +4.65%

Real-time BOERSE MUENCHEN

Last update June 28, 2024 at 03:45 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying GSK PLC
IssuerLogo Issuer UniCredit UniCredit
WKN HD0345
ISINDE000HD03455
Date issued 2023-10-23
Strike 1,700 p
Maturity 2024-09-18 (81 Days)
Parity 1 : 1
Emission price 0.63
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 1.9
Lowest since issue 0.16
Delta0.21x
Omega 17.34
Premium12.34x
Gearing83.94x
Moneyness 0.8997
Difference Strike 170.5 p
Difference Strike %+10.03%
Spread 0.03
Spread %13.04%
Theoretical value 0.2250
Implied Volatility 23.16 %
Total Loss Probability 81.93 %
Intrinsic value 0.000000
Present value 0.2250
Break even 1,719.06 €
Theta-0.03x
Vega0.02x
Rho0.01x

Company Profile

GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Sector
-
More about the company

Ratings for GSK plc

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Consensus: GSK plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
15.3 GBP
Average target price
20.28 GBP
Spread / Average Target
+32.62%
Consensus